1. |
Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J, 2008, 31(1): 143-178.
|
2. |
Garantziotis S, Schwartz DA. Ecogenomics of respiratory diseases of public health significance. Annu Rev Public Health, 2010, 31: 37-51.
|
3. |
Akinbami L. Centers for disease control and prevention national center for health statistics. The state of childhood asthma. Adv Data, 2006, 12(381): 1-24.
|
4. |
尚云晓, 冯雍. 2014版全球哮喘防治创议(GINA)解读——与儿童哮喘相关内容. 中国实用内科杂志, 2014, 29(9): 669-672.
|
5. |
Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: World Allergy Organization position paper 2009. World Allergy Organ, 2009, 2(11): 233-281.
|
6. |
Linkov G, Toskala E. Sublingual immunotherapy: what we can learn from the European experience. Curr Opin Otolaryngol Head Neck Surg, 2014, 22(3): 208-210.
|
7. |
Jay DC, Nadeau KC. Immune mechanisms of sublingual immunotherapy. Curr Allergy Asthma Rep, 2014, 14(11): 473.
|
8. |
Cavkaytar O, Akdis CA, Akdis M. Modulation of immune responses by immunotherapy in allergic diseases. Curr Opin Pharmacol, 2014, 17(1): 30-37.
|
9. |
Scadding GK, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy, 1986, 16(5): 483-491.
|
10. |
Olaguíbel JM, Alvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J Investig Allergol Clin Immunol, 2005, 15(1): 9-16.
|
11. |
Potter PC. Update on sublingual immunoltherapy. Ann Allergy Asthma Immunol, 2006, 96(Suppl 1): S22-S25.
|
12. |
Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for all ergic diseases. A WHO position paper. J Allergy Clin Immunol, 1998, 102(4 Pt 1): 558-562.
|
13. |
Bousquet J, Van Cauwenberge P. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol, 2001, 3(Suppl 5): S146-S150.
|
14. |
周真, 崔玉霞. 尘螨过敏性支气管哮喘的舌下免疫治疗研究进展. 国际儿科学杂志, 2011, 38(1): 56-58.
|
15. |
Papadopoulos NG, Arakawa H, Carlsen KH, et al. International consensus on (ICON) pediatric asthma. Allergy, 2012, 67(8): 976-997.
|
16. |
Agache I, Akdis C, Jutel M, et al. Untangling asthma phenotypes and endotypes. Allergy, 2012, 67(7): 835-846.
|
17. |
Jutel M, Akdis CA. T-cell subset regulation in atopy. Curr Allergy Asthma Rep, 2011, 11(2): 139-145.
|
18. |
Viswanathan RK, Busse WW. Allergen immunotherapy in allergic respiratory diseases: from mechanisms to meta-analyses. Chest, 2012, 141(5): 1303-1314.
|
19. |
Eifan AO, Akkoc T, Yildiz A, et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy, 2010, 40(6): 922-932.
|
20. |
Ferrés J, Justicia JL, García MP, et al. Efficacy of high-dose sublingual immunotherapy in children allergic to house dust mites in real-life clinical practice. Allergol Immunopathol (Madr), 2011, 39(3): 122-127.
|
21. |
马香萍, 多力坤. 舌下特异性免疫治疗对尘螨过敏性哮喘儿童的作用. 中国当代儿科杂志, 2010, 12(5): 344-347.
|
22. |
Marogna M, Spadolini I, Massolo A, et al. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol, 2010, 126(5): 969-975.
|
23. |
Durham SR, Emminger W, Kapp A, et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol, 2010, 125(1): 131-138.
|
24. |
Keles S, Karakoc-Aydiner E, Ozen A, et al. A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes. J Allergy Clin Immunol, 2011, 128(4): 808-815.
|
25. |
Mosbech H. Tolerability and efficacy of house dust mite AIT. Allergy, 2011, 66(Suppl 95): S55-S56.
|
26. |
Yukselen A, Kendirli SG, Yilmaz M, et al. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. Int Arch Allergy Immunol, 2012, 157(3): 288-298.
|
27. |
Larenas-Linnemann D, Blaiss M, Van Bever HP, et al. Pediatric sublingual immunotherapy efficacy: evidence analysis, 2009-2012. Ann Allergy Asthma Immunol, 2013, 110(6): 402-415.
|
28. |
Tao L, Shi B, Shi G, et al. Efficacy of sublingual immunotherapy for allergic asthma: retrospective meta-analysis of randomized, double-blind and placebo-controlled trials. Clin Respir J, 2014, 8(2): 192-205.
|
29. |
丁莲富, 陈强, 李岚, 等. 舌下特异性免疫治疗过敏性鼻炎/过敏性哮喘患儿IL-17和IL-35水平的变化及临床疗效. 中国当代儿科杂志, 2014, 16(12): 1206-1210.
|
30. |
Liao W, Hu Q, Shen L, et al. Sublingual immunotherapy for asthmatic children sensitized to house dust mite: a Meta-Analysis. Medicine (Baltimore), 2015, 94(24): e701.
|
31. |
Rienzo D, Minelli M, Musarra A, et al. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy, 2005, 35(5): 560-564.
|
32. |
Yukselen A, Kendirli SG. Role of immunotherapy in the treatment of allergic asthma. World J Clin Cases, 2014, 2(12): 859-865.
|
33. |
Kleine-Tebbe J, Ribel M, Herold DA. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy, 2006, 61(2): 181-184.
|
34. |
Calderón MA, Casale TB, Togias A, et al. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol, 2011, 127(1): 30-38.
|
35. |
Calderón MA, Simons FE, Malling HJ, et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy, 2012, 67(3): 302-311.
|
36. |
Vovolis V, Kalogiros L, Mitsias D, et al. Severe repeated anaphylactic reactions to sublingual immunotherapy. Allergol Immunopathol (Madr), 2013, 41(4): 279-281.
|
37. |
Cox L, Compalati E, Kundig T, et al. New directions in immunotherapy. Curr Allergy Asthma Rep, 2013, 13(2): 178-195.
|
38. |
Passalacqua G, Baena-Cagnani CE, Bousquet J, et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol, 2013, 132(1): 93-98.
|
39. |
Cromwell O, Haefner D, Nandy A. Recombinant allergens for specific immunotherapy. J Allergy Clin Immunol, 2011, 127(4): 865-872.
|
40. |
Lin SY, Erekosima N, Kim JM, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA, 2013, 309(12): 1278-1288.
|
41. |
Kim JM, Lin SY, Suarez-Cuervo C, et al. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review. Pediatrics, 2013, 131(6): 1155-1167.
|
42. |
Holt PG, Sly PD, Sampson HA, et al. Prophylactic use of sublingual allergen immunotherapy in high-risk children: a pilot study. J Allergy Clin Immunol, 2013, 132(4): 991-993.
|